Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis-Reference-Cited by-同舟云学术

Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis

Published:2019-12-28 Issue:2 Volume:2 Page:90-105
ISSN:2573-9832
Container-title:FASEB BioAdvances
language:en
Short-container-title:FASEB BioAdvances

Author:

Howell Mark C.¹²,Green Ryan¹²,Khalil Roukiah¹,Foran Elspeth¹,Quarni Waise¹,Nair Rajesh³,Stevens Stanley⁴,Grinchuk Aleksandr¹,Hanna Andrew¹,Mohapatra Shyam²⁵⁶,Mohapatra Subhra¹²⁶

Affiliation:

1. Molecular Medicine Department University of South Florida Tampa FL USA

2. Center for Research & Education in Nanobioengineering University of South Florida Tampa FL USA

3. Transgenex Nanobiotech Inc Tampa FL USA

4. Cell Biology, Microbiology, and Molecular Biology College of Arts and Sciences University of South Florida Tampa FL USA

5. Division of Translational Medicine Internal Medicine Morsani College of Medicine University of South Florida Tampa FL USA

6. James A Haley Veterans Hospital Tampa FL USA

Funder

Office of Research and Development

U.S. Department of Veterans Affairs

National Institutes of Health

University of South Florida

Publisher

Wiley

Subject

Cancer Research,Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Medicine,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fba.2019-00081

Reference56 articles.

1. Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance: Figure 1.

2. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

3. Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review

4. Lapatinib, a dual‐targeted small molecule inhibitor of Egfr and Her2, in Her2‐amplified breast cancer: from bench to bedside;Tsang RY;Clin Med Insights: Ther,2011

5. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel;Cancers;2024-05-25

2. Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma;International Journal of Molecular Sciences;2024-03-06

3. Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?;Cancer and Metastasis Reviews;2024-03

4. EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth;Cancer Discovery;2024-01-25

5. How Neuromembrane Lipids Modulate Membrane Proteins: Insights from G-Protein-Coupled Receptors (GPCRs) and Receptor Tyrosine Kinases (RTKs);Cold Spring Harbor Perspectives in Biology;2023-07-24